Medilink Therapeutics
company
About
Medilink Therapeutics is a biotech company focusing on next-generation antibody-drug conjugate Research & development.
- Suzhou,Jiangsu,China
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $70M
- Industries
- Biotechnology,Genetics,Therapeutics
- Founded date
- Jan 1, 2020
- Operating Status
- Active
- Legal Name
- Suzhou Medilink Therapeutics Ltd.
- Also Known As
- Suzhou Medilink Therapeutics
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$120M
Medilink Therapeutics has raised a total of
$120M
in funding over 2 rounds. Their latest funding was raised on
Mar 14, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 14, 2022 | Series B | $70M | 5 |
LYFE Capital
Qiming Venture Partners
|
— | Detail |
| Mar 1, 2021 | Series A | $50M | 3 |
Apricot Capital
Loyal Valley Capital
Qiming Venture Partners
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
5
6
Medilink Therapeutics is funded by 6 investors.
LYFE Capital
and Qiming Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
LYFE Capital
|
Yes | Series B |
|
Qiming Venture Partners
|
Yes | Series B |
|
Apricot Capital
|
Yes | Series A |
Highlight Capital
|
— | Series B |
Legend Capital
|
— | Series B |
|
Loyal Valley Capital
|
— | Series B |
Employee Profiles
Number of Employee Profiles
1
Medilink Therapeutics has 1 current employee profiles, including
Executive Tongtong Xue
Executive
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
